Vaccine-relevant human papillomavirus (HPV) infections and future acquisition of high-risk HPV types in men

Journal of Infectious Diseases

Volumn 206, Issue 5, 2012, Pages 669-677

  Rositch, Anne F ^a   Hudgens, Michael G ^b   Backes, Danielle M ^a   Moses, Stephen ^e   Agot, Kawango ^f   Nyagaya, Edith ^e   Snijders, Peter J F ^g   Meijer, Chris J L M ^g   Bailey, Robert C ^d   Smith, Jennifer S ^a,c  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b University of North Carolina at Chapel Hill   (United States)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

^d UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^e UNIVERSITY OF MANITOBA   (Canada)

^f IMPACT RESEARCH AND DEVELOPMENT ORGANIZATION   (Kenya)

^g VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS DNA; WART VIRUS VACCINE;

ADULT; ARTICLE; CIRCUMCISION; COHORT ANALYSIS; CONTROLLED STUDY; FOLLOW UP; GENOTYPE; HIGH RISK POPULATION; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 31; HUMAN PAPILLOMAVIRUS TYPE 45; HUMAN PAPILLOMAVIRUS TYPE 6; KENYA; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PAPILLOMAVIRUS INFECTION; PRIORITY JOURNAL;

ADOLESCENT; COHORT STUDIES; DNA, VIRAL; GENOTYPE; HUMANS; INCIDENCE; KAPLAN-MEIER ESTIMATE; KENYA; MALE; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; POLYMERASE CHAIN REACTION; PROSPECTIVE STUDIES; QUESTIONNAIRES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; YOUNG ADULT;

EID: 84864946551     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jis406     Document Type: Article

References (46)

1. Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999; 189:12-9. (Pubitemid 29406813)
2. Bosch FX, Lorincz A, Munoz N, Meijer C, Shah KV. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 2002; 55:244-65. (Pubitemid 34293391)
3. Lajous M, Mueller N, Cruz-Valdez A, et al. Determinants of prevalence, acquisition, and persistence of human papillomavirus in healthy Mexican military men. Cancer Epidemiol Biomarkers Prev 2005; 14:1710-6. (Pubitemid 40995084)
4. Giuliano AR, Lazcano-Ponce E, Villa LL, et al. The human papillomavirus infection in men study: human papillomavirus prevalence and type distribution among men residing in Brazil, Mexico, and the United States. Cancer Epidemiol Biomarkers Prev 2008; 17:2036-43.
5. Kjaer SK, Munk C, Winther JF, Jorgensen HO, Meijer CJ, van den Brule AJ. Acquisition and persistence of human papillomavirus infection in younger men: a prospective follow-up study among Danish soldiers. Cancer Epidemiol Biomarkers Prev 2005; 14:1528-33. (Pubitemid 40807357)
6. Ng'ayo MO, Bukusi E, Rowhani-Rahbar A, et al. Epidemiology of human papillomavirus infection among fishermen along Lake Victoria Shore in the Kisumu District, Kenya. Sex Transm Infect 2008; 84:62-6. (Pubitemid 351195856)
7. Nielson CM, Harris RB, Flores R, et al. Multiple-type human papillomavirus infection in male anogenital sites: prevalence and associated factors. Cancer Epidemiol Biomarkers Prev 2009; 18:1077-83.
8. Shin HR, Franceschi S, Vaccarella S, et al. Prevalence and determinants of genital infection with papillomavirus, in female and male university students in Busan, South Korea. J Infect Dis 2004; 190:468-76. (Pubitemid 38982082)
9. Serwadda D, Wawer MJ, Makumbi F, et al. Circumcision of HIV-infected men: effects on high-risk human papillomavirus infections in a randomized trial in Rakai, Uganda. J Infect Dis 2010; 201:1463-9.
10. FDA Licensure of quadrivalent human papillomavirus vaccine (HPV4, Gardasil) for use in males and guidance from the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2010;59:630-632
11. Mendez F, Munoz N, Posso H, et al. Cervical coinfection with human papillomavirus (HPV) types and possible implications for the prevention of cervical cancer by HPV vaccines. J Infect Dis 2005; 192: 1158-65. (Pubitemid 41368414)
12. Dillner J, Arbyn M, Dillner L. Translational mini-review series on vaccines: monitoring of human papillomavirus vaccination. Clin Exp Immunol 2007; 148:199-207. (Pubitemid 46591311)
13. Chaturvedi AK, Myers L, Hammons AF, et al. Prevalence and clustering patterns of human papillomavirus genotypes in multiple infections. Cancer Epidemiol Biomarkers Prev 2005; 14:2439-45. (Pubitemid 41437849)
14. Vaccarella S, Franceschi S, Snijders PJ, Herrero R, Meijer CJ, Plummer M. Concurrent infection with multiple human papillomavirus types: pooled analysis of the IARC HPV Prevalence Surveys. Cancer Epidemiol Biomarkers Prev 2010; 19:503-10.
15. Vaccarella S, Plummer M, Franceschi S, et al. Clustering of human papillomavirus (HPV) types in the male genital tract: the HPV in men (HIM) study. J Infect Dis 2011; 204:1500-4.
16. Vaccarella S, Franceschi S, Herrero R, et al. Clustering of multiple human papillomavirus infections in women from a population-based study in Guanacaste, Costa Rica. J Infect Dis 2011; 204:385-90.
17. Chaturvedi AK, Katki HA, Hildesheim A, et al. Human papillomavirus infection with multiple types: pattern of coinfection and risk of cervical disease. J Infect Dis 2011; 203:910-20.
18. Liaw KL, Hildesheim A, Burk RD, et al. A prospective study of human papillomavirus (HPV) type 16 DNA detection by polymerase chain reaction and its association with acquisition and persistence of other HPV types. J Infect Dis 2001; 183:8-15. (Pubitemid 32043036)
19. Plummer M, Schiffman M, Castle PE, Maucort-Boulch D, Wheeler CM. A 2-year prospective study of human papillomavirus persistence among women with a cytological diagnosis of atypical squamous cells of undetermined significance or low-grade squamous intraepithelial lesion. J Infect Dis 2007; 195:1582-9. (Pubitemid 46799215)
20. Rousseau MC, Pereira JS, Prado JC, Villa LL, Rohan TE, Franco EL. Cervical coinfection with human papillomavirus (HPV) types as a predictor of acquisition and persistence of HPV infection. J Infect Dis 2001; 184:1508-17. (Pubitemid 33139735)
21. Thomas KK, Hughes JP, Kuypers JM, et al. Concurrent and sequential acquisition of different genital human papillomavirus types. J Infect Dis 2000; 182:1097-102.
22. Dunne EF, Nielson CM, Stone KM, Markowitz LE, Giuliano AR. Prevalence of HPV infection among men: a systematic review of the literature. J Infect Dis 2006; 194:1044-57. (Pubitemid 44547644)
23. Bruni L, Diaz M, Castellsague X, Ferrer E, Bosch FX, de Sanjose S. Cervical human papillomavirus prevalence in 5 continents: metaanalysis of 1 million women with normal cytological findings. J Infect Dis 2010; 202:1789-99.
24. Bailey RC, Moses S, Parker CB, et al. Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial. Lancet 2007; 369:643-56. (Pubitemid 46281312)
25. Smith JS, Backes DM, Hudgens MG, et al. Prevalence and risk factors of human papillomavirus infection by penile site in uncircumcised Kenyan men. Int J Cancer 2010; 126:572-7.
26. Smith JS, Moses S, Hudgens MG, et al. Human papillomavirus detection by penile site in young men from Kenya. Sex Transm Dis 2007; 34:928-34. (Pubitemid 350287510)
27. Gray RH, Serwadda D, Kong X, et al. Male circumcision decreases acquisition and increases clearance of high-risk human papillomavirus in HIV-negative men: a randomized trial in Rakai, Uganda. J Infect Dis 2010; 201:1455-62.
28. Westercamp N, Bailey RC. Acceptability of male circumcision for prevention of HIV/AIDS in sub-Saharan Africa: a review. AIDS Behav 2007; 11:341-55. (Pubitemid 46570814)
29. van den Brule AJ, Pol R, Fransen-Daalmeijer N, Schouls LM, Meijer CJSnijders PJ. GP5+/6+ PCR followed by reverse line blot analysis enables rapid and high-throughput identification of human papillomavirus genotypes. J Clin Microbiol 2002; 40:779-87. (Pubitemid 34208623)
30. Snijders PJF, van den Brule A, Jacobs MV, Pol RP, Meijer CJLM. HPV DNA detection and typing in cervical scrapes by general primer GP5 +/6+ PCR. In: Davy CE, Doorbar J, eds. Methods in molecular medicine: human papillomaviruses-methods and protocols. Totowa, NJ: Humana Press; 2005:101-14.
31. Harper DM, Franco EL, Wheeler C, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 2004; 364:1757-65. (Pubitemid 39488060)
32. Villa LL, Costa RL, Petta CA, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 2005; 6:271-8. (Pubitemid 40590263)
33. Paavonen J, Naud P, Salmeron J, et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 2009; 374:301-14.
34. Kong X, Archer KJ, Moulton LH, Gray RH, Wang MC. Parametric frailty models for clustered data with arbitrary censoring: application to effect of male circumcision on HPV clearance. BMC Med Res Methodol 2010; 10:40.
35. Peto R. Experimental survival curves for interval-censored data. J R Stat Soc Ser C Appl Stat 1973; 22:86-91.
36. Turnbull BW. The empirical distribution function with arbitrarily grouped, censored and truncated data. J R Stat Soc Series B 1976; 38:290-5.
37. So Y, Johnston G, Kim SH. Analyzing interval-censored survival data with SAS® software. Proceedings of the SAS® Global Forum 2010 Conference. Cary, NC: SAS Institute Inc.; 2010.
38. Sun J, Zhao Q, Zhao X. Generalized log-rank tests for intervalcensored failure time data. Scand Stat 2005; 32:49-57. (Pubitemid 40322552)
39. Allison P. Survival analysis using SAS: a practical guide. 2nd ed. Cary, NC: SAS Institute; 2010.
40. Rositch AF, Poole C, Hudgens MG, et al. Multiple human papillomavirus infections and type competition in men. J Infect Dis 2012; 205:72-81.
41. Soderlund-Strand A, Carlson J, Dillner J. Modified general primer PCR system for sensitive detection of multiple types of oncogenic human papillomavirus. J Clin Microbiol 2009; 47:541-6.
42. Qu W, Jiang G, Cruz Y, et al. PCR detection of human papillomavirus: comparison between MY09/MY11 and GP5+/GP6+ primer systems. J Clin Microbiol 1997; 35:1304-10. (Pubitemid 27216785)
43. Hernandez BY, Wilkens LR, Zhu X, et al. Circumcision and human papillomavirus infection in men: a site-specific comparison. J Infect Dis 2008; 197:787-94. (Pubitemid 351417000)
44. Merikukka M, Kaasila M, Namujju PB, et al. Differences in incidence and co-occurrence of vaccine and nonvaccine human papillomavirus types in Finnish population before human papillomavirus mass vaccination suggest competitive advantage for HPV33. Int J Cancer 2011; 128:1114-9.
45. Ho GY, Studentsov Y, Hall CB, et al. Risk factors for subsequent cervicovaginal human papillomavirus (HPV) infection and the protective role of antibodies to HPV-16 virus-like particles. J Infect Dis 2002; 186:737-42. (Pubitemid 35013424)
46. Safaeian M, Porras C, Schiffman M, et al. Epidemiological study of anti-HPV16/18 seropositivity and subsequent risk of HPV16 and -18 infections. J Natl Cancer Inst 2010; 102:1653-62.